Equities
Health CareMedical Equipment and Services
  • Price (SEK)184.10
  • Today's Change-3.20 / -1.71%
  • Shares traded66.41k
  • 1 Year change+31.69%
  • Beta1.5787
Data delayed at least 15 minutes, as of Jul 11 2025 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.

  • Revenue in SEK (TTM)10.42bn
  • Net income in SEK309.00m
  • Incorporated2014
  • Employees2.25k
  • Location
    AddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
  • Phone+46 842003830
  • Websitehttps://www.add.life/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALIF B:STO since
announced
Transaction
value
Edge Medical LtdDeal completed01 Apr 202501 Apr 2025Deal completed27.05%10.33m
Data delayed at least 15 minutes, as of Jul 11 2025 17:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellaVision AB747.94m152.12m4.36bn228.0028.695.2122.735.846.386.3831.3635.160.74131.957.583,169,233.0015.0814.5917.1217.1068.4868.0520.3419.642.6840.330.026738.496.789.397.997.2533.00--
Xvivo Perfusion AB854.98m137.00m6.34bn190.0046.603.0328.307.424.324.3227.0366.430.37591.134.844,499,900.006.023.046.513.2675.0573.7416.0210.863.58--0.01380.0037.6330.0887.52103.4618.21--
Surgical Science Sweden AB946.54m141.09m7.50bn336.0053.161.6836.497.922.772.7718.5587.730.19211.687.203,454,507.002.863.913.034.1868.3768.9414.9121.553.25--0.00040.000.139854.17-43.7359.8939.76--
Revenio Group Oyj1.18bn213.43m8.25bn246.0038.616.5730.256.970.71610.71613.974.210.76042.997.06439,489.6013.7814.1115.9217.5371.0470.9618.1220.612.1824.430.101853.127.1915.91-3.2014.6422.935.92
Arjo AB (publ)11.40bn458.00m8.61bn7.00k20.141.185.520.75511.681.6841.8428.780.72844.756.431,588,736.002.923.584.135.4543.5043.974.015.350.68534.620.399744.322.844.823.754.32-12.317.89
RaySearch Laboratories AB (publ)1.27bn223.62m9.96bn422.0053.3812.9422.857.876.526.5236.9326.890.61448.173.143,044,546.0010.852.9616.364.3791.8890.9317.665.801.52217.600.327767.9016.629.96149.4932.190.5132--
Biotage AB1.96bn255.00m11.43bn622.0044.872.9726.285.833.183.1824.4848.050.3981.667.442,913,819.005.188.475.869.9362.6261.6213.0015.071.5624.710.058348.019.8313.3015.458.7430.04--
ChemoMetec A/S688.27m253.24m14.02bn184.0055.3715.6649.9220.379.729.7226.4134.360.69430.73156.342,656,324.0025.5527.9630.4335.1080.0679.5736.7935.022.92--0.0128144.08-8.2218.37-23.7226.649.97-11.81
Elekta AB (publ)18.02bn237.00m17.68bn4.54k77.262.0811.490.98120.62070.620747.1523.040.59673.733.053,972,002.000.79153.481.416.2137.8038.221.336.020.863413.350.46192.20-0.56854.29-81.80-26.2215.565.92
Vitrolife AB3.61bn498.00m19.83bn1.15k39.841.5121.075.493.673.6726.6396.910.21543.645.973,222,322.002.97-3.383.08-3.5259.3258.0613.80-17.403.088.140.1294--2.7619.51113.326.0318.32--
Embla Medical hf8.20bn689.99m20.84bn4.08k30.222.7316.862.541.081.0812.7811.930.54752.146.691,342,645.004.643.775.484.4263.1962.228.476.601.104.850.39730.008.814.4916.940.66884.25--
AddLife AB10.42bn309.00m21.70bn2.25k72.614.3819.292.082.542.5485.4941.990.81383.915.794,617,908.002.434.453.647.0037.5837.392.995.130.52523.010.48333.596.2124.2132.6312.3828.288.45
Data as of Jul 11 2025. Currency figures normalised to AddLife AB's reporting currency: Swedish Krona SEK

Institutional shareholders

52.53%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 30 May 202510.84m9.20%
AMF Fonder ABas of 31 Dec 202410.70m9.08%
ODIN Forvaltning ASas of 30 May 20257.90m6.70%
Cliens Kapitalf�rvaltning ABas of 31 Dec 20246.63m5.63%
F�rsta AP-fondenas of 31 Dec 20246.10m5.18%
Fidelity Management & Research Co. LLCas of 19 Nov 20246.09m5.17%
The Vanguard Group, Inc.as of 02 Jul 20254.03m3.42%
Tredje AP-fondenas of 31 Dec 20243.33m2.82%
ODIN Forvaltning AS (Sweden)as of 30 May 20253.27m2.77%
Fj�rde AP-fondenas of 30 Jun 20243.04m2.58%
More ▼
Data from 31 Mar 2025 - 30 May 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.